Leading science, pioneering therapies
CRM Publications

Notch3 drives development and progression of cholangiocarcinoma.

TitleNotch3 drives development and progression of cholangiocarcinoma.
Publication TypeJournal Article
Year of Publication2016
AuthorsGuest RV, Boulter L, Dwyer BJ, Kendall TJ, Man T-Y, Minnis-Lyons SE, Lu W-Y, Robson AJ, Gonzalez SFerreira, Raven A, Wojtacha D, Morton JP, Komuta M, Roskams T, Wigmore SJ, Sansom OJ, Forbes SJ
JournalProc Natl Acad Sci U S A
Volume113
Issue43
Pagination12250-12255
Date Published2016 Oct 25
ISSN1091-6490
Abstract

The prognosis of cholangiocarcinoma (CC) is dismal. Notch has been identified as a potential driver; forced exogenous overexpression of Notch1 in hepatocytes results in the formation of biliary tumors. In human disease, however, it is unknown which components of the endogenously signaling pathway are required for tumorigenesis, how these orchestrate cancer, and how they can be targeted for therapy. Here we characterize Notch in human-resected CC, a toxin-driven model in rats, and a transgenic mouse model in which p53 deletion is targeted to biliary epithelia and CC induced using the hepatocarcinogen thioacetamide. We find that across species, the atypical receptor NOTCH3 is differentially overexpressed; it is progressively up-regulated with disease development and promotes tumor cell survival via activation of PI3k-Akt. We use genetic KO studies to show that tumor growth significantly attenuates after Notch3 deletion and demonstrate signaling occurs via a noncanonical pathway independent of the mediator of classical Notch, Recombinant Signal Binding Protein for Immunoglobulin Kappa J Region (RBPJ). These data present an opportunity in this aggressive cancer to selectively target Notch, bypassing toxicities known to be RBPJ dependent.

DOI10.1073/pnas.1600067113
Alternate JournalProc. Natl. Acad. Sci. U.S.A.
PubMed ID27791012
PubMed Central IDPMC5086988
Publication institute
CRM